Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Controlled human infection models in COVID-19 and tuberculosis: current progress and future challenges.

Morrison H. et al, (2023), Front Immunol, 14

Practical considerations for a TB controlled human infection model (TB-CHIM); the case for TB-CHIM in Africa, a systematic review of the literature and report of 2 workshop discussions in UK and Malawi.

Gordon SB. et al, (2023), Wellcome Open Res, 8

Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants.

Satti I. et al, (2022), Nat Commun, 13

Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study.

Wilkie M. et al, (2022), Sci Rep, 12

Tuberculosis vaccines in the era of Covid-19 - what is taking us so long?

Dockrell HM. and McShane H., (2022), EBioMedicine, 79

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.

Killingley B. et al, (2022), Nat Med

Challenges in Developing a Controlled Human Tuberculosis Challenge Model.

Jackson S. and McShane H., (2022), Curr Top Microbiol Immunol

Rapid research response to the COVID-19 pandemic: perspectives from a National Institute for Health Biomedical Research Centre.

Henderson LR. et al, (2022), Health Res Policy Syst, 20

"It seems impossible that it's been made so quickly": a qualitative investigation of concerns about the speed of COVID-19 vaccine development and how these may be overcome.

Brown P. et al, (2022), Hum Vaccin Immunother, 1 - 8

Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop.

Williams E. et al, (2022), Vaccine

Healthy volunteer experience following research bronchoscopy

Morrison H. et al, (2022), EUROPEAN RESPIRATORY JOURNAL, 60

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial.

Fisher BA. et al, (2021), Lancet Respir Med

A large National Institute for Health Research (NIHR) Biomedical Research Centre facilitates impactful cross-disciplinary and collaborative translational research publications and research collaboration networks: a bibliometric evaluation study.

Kiparoglou V. et al, (2021), J Transl Med, 19

Assessment of the reproducibility and inter-site transferability of the murine direct splenocyte mycobacterial growth inhibition assay (MGIA)

MCSHANE H. and TANNER R., (2021), bioRxiv.

Induction of specific antibodies, IgG-secreting plasmablasts and memory B cells following BCG vaccination

MCSHANE H. and TANNER R., (2021), bioRxiv

Tuberculosis vaccines: beyond bacille Calmette-Guerin

MCSHANE H., (2021), Philosophical Transactions of the Royal Society of London: Biological Sciences

SARS-CoV-2 Human Challenge Studies. Reply.

Rapeport G. et al, (2021), N Engl J Med

Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease.

Burel JG. et al, (2021), Tuberculosis (Edinb), 131

High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation.

Sibley L. et al, (2021), Sci Rep, 11

Injection fears and COVID-19 vaccine hesitancy

FREEMAN D., (2021), Psychological Medicine

Load More

Include forthcoming?